Explore / Peer-reviewed article
Peer-reviewed article

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.

Ellis SiD, Bostian C, Donnelly A, Feng W, Eisen KiD, Lean MiD, Conlan E, Ostacher MiD, Aaronson S, Suppes T

Journal of affective disordersJun 9, 2025United States1 citationsDOI: 10.1016/j.jad.2025.119655

Abstract

<h4>Background</h4>One-third of Veterans with major depressive disorder suffer from treatment-resistant depression (TRD). This is the first study to evaluate the long-term outcomes of psilocybin in Veterans with severe TRD.<h4>Methods</h4>This paper presents 12-month results from an open-label pilot study assessing the effects of 25 mg psilocybin in Veterans with severe TRD, defined as a major depressive episode failing to respond to ≥5 treatments, or lasting >2 years. 10 out of 15 participants completed the 12-month follow-up. Depression severity was measured by Montgomery-Åsberg Depression Rating scale (MADRS) at 6, 9, and 12 months posttreatment. Response was defined as ≥50 % reduction in MADRS, and remission as ≤10 MADRS score.<h4>Results</h4>Depression scores show significant reductions from Baseline across all timepoints. However, there was an increase in MADRS scores from short-term timepoints (Weeks 3 and 12) to Month 12. Of 10 participants, at Month 6, 80 % met response and 50 % met remission criteria for the MADRS. At Month 9, acute responses began to wane. At Month 12, 40 % maintained response and 30 % maintained remission.<h4>Limitations</h4>Limitations include the small sample size and the uncontrolled, unblinded design.<h4>Conclusions</h4>In this first-of-kind study on long-term effects of psilocybin for Veterans with severe TRD, depression scores showed significant sustained reductions up to 12-months. However, the antidepressant effects began to wane at 6 months, and then more substantially after 9 months, although these increases in MADRS did not reach statistical significance. Further research is needed.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT04433858.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

VeteransTreatment-resistant DepressionLong-term OutcomesPsychedelics

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.